Gaush Meditech (HKG:2407) expects to report a net profit of 13.9 million yuan to 16.7 million yuan for the first half of 2026, down 53.5% to 61.3% from 35.9 million yuan a year earlier.
The company attributed the expected decline to lower revenue amid shifts in market demand driven by national policies, the termination of its agency partnership for overseas femtosecond laser-assisted cataract surgery products, and exchange rate fluctuations, according to a Thursday Hong Kong bourse filing.
Shares of the company fell over 7% in recent trade.